Agios Pharmaceuticals, Inc. (AGIO)
Largest Insider Buys in Sector
AGIO Stock Price History Chart
AGIO Stock Performance
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Agios Pharmaceuticals, Inc.
Over the last 12 months, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $9.9M worth of Agios Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $5.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,322 shares for transaction amount of $1.25M was made by FOUSE JACQUALYN A (Chief Executive Officer) on 2019‑11‑13.
List of Insider Buy and Sell Transactions, Agios Pharmaceuticals, Inc.
| 2025-01-06 | Sale | Chief Commercial Officer | 2,804 0.0047% | $32.18 | $90,233 | -0.72% | ||
| 2024-12-11 | Sale | director | 200 0.0004% | $46.28 | $9,256 | -22.67% | ||
| 2024-11-08 | Sale | director | 10,000 0.0432% | $58.19 | $581,911 | -22.08% | ||
| 2024-11-08 | Sale | Principal Accounting Officer | 772 0.0032% | $56.09 | $43,301 | -22.08% | ||
| 2024-11-07 | Sale | Chief Legal Officer | 21,752 0.0844% | $52.21 | $1.14M | -14.07% | ||
| 2024-11-07 | Sale | director | 10,000 0.0398% | $53.52 | $535,236 | -14.07% | ||
| 2024-09-26 | Sale | Chief Financial Officer | 2,542 0.0093% | $49.03 | $124,634 | -7.12% | ||
| 2024-08-08 | Sale | Chief Executive Officer | 11,091 0.0352% | $42.75 | $474,140 | +2.96% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 3,705 0.0121% | $43.85 | $162,464 | +3.94% | ||
| 2024-06-05 | Sale | Chief Executive Officer | 12,115 0.044% | $48.84 | $591,697 | -7.67% | ||
| 2024-06-03 | Sale | Principal Accounting Officer | 1,362 0.0045% | $44.39 | $60,459 | +2.90% | ||
| 2024-04-10 | Sale | director | 7,791 0.0159% | $27.55 | $214,642 | +48.06% | ||
| 2024-03-07 | Sale | director | 1,285 0.003% | $31.62 | $40,632 | +38.83% | ||
| 2024-03-06 | Sale | director | 4,415 0.0105% | $31.99 | $141,236 | +36.80% | ||
| 2024-03-05 | Sale | Chief Executive Officer | 4,156 0.0101% | $32.57 | $135,361 | +38.46% | ||
| 2024-03-05 | Sale | Chief Medical Officer | 2,642 0.0064% | $32.57 | $86,050 | +38.46% | ||
| 2024-03-05 | Sale | Chief Legal Officer | 2,642 0.0064% | $32.57 | $86,050 | +38.46% | ||
| 2024-03-05 | Sale | Chief Financial Officer | 672 0.0016% | $32.57 | $21,887 | +38.46% | ||
| 2024-03-05 | Sale | director | 300 0.0007% | $32.21 | $9,663 | +38.46% | ||
| 2024-03-05 | Sale | Principal Accounting Officer | 3,127 0.0074% | $32.07 | $100,278 | +38.46% |
Insider Historical Profitability
| FOUSE JACQUALYN A | director | 137396 0.2409% | $32.42 | 1 | 4 | +28.93% |
| Schenkein David P | director | 122854 0.2154% | $32.42 | 1 | 58 | +28.93% |
| Goff Brian | Chief Executive Officer | 78792 0.1382% | $32.42 | 0 | 7 | |
| Gheuens Sarah | Chief Medical Officer | 43736 0.0767% | $32.42 | 0 | 6 | |
| Jones Cecilia | Chief Financial Officer | 20158 0.0353% | $32.42 | 0 | 5 | |
| Milanova Tsveta | Chief Commercial Officer | 18906 0.0332% | $32.42 | 0 | 4 | |
| Burns James William | Chief Legal Officer | 15700 0.0275% | $32.42 | 0 | 7 | |
| Scadden David | director | 15483 0.0271% | $32.42 | 1 | 1 | <0.0001% |
| Ballal Rahul D. | director | 7992 0.014% | $32.42 | 0 | 2 | |
| Foster-Cheek Kaye I | director | 5524 0.0097% | $32.42 | 0 | 6 | |
| Washburn Theodore James Jr. | Principal Accounting Officer | 813 0.0014% | $32.42 | 0 | 13 | |
| Celgene European Investment Co LLC | 10 percent owner | 1856353 3.255% | $32.42 | 4 | 0 | +32.26% |
| CELGENE CORP /DE/ | 10 percent owner | 1777824 3.1173% | $32.42 | 2 | 0 | +14.63% |
| Tessier-Lavigne Marc | director | 101009 0.1771% | $32.42 | 1 | 0 | <0.0001% |
| Cantley Lewis Clayton Jr. | director | 79475 0.1394% | $32.42 | 0 | 60 | |
| Higgons John Duncan | Chief Operating Officer | 61835 0.1084% | $32.42 | 0 | 31 | |
| MARAGANORE JOHN | director | 36209 0.0635% | $32.42 | 4 | 2 | +52.79% |
| Biller Scott | Chief Scientific Officer | 26511 0.0465% | $32.42 | 0 | 58 | |
| Bowden Christopher | Chief Medical Officer | 15487 0.0272% | $32.42 | 0 | 26 | |
| Hoerter Steven L. | Chief Commercial Officer | 10941 0.0192% | $32.42 | 0 | 10 | |
| Miles Darrin | Chief Commercial Officer | 7209 0.0126% | $32.42 | 0 | 3 | |
| NELSEN ROBERT | director | 0 0% | $32.42 | 0 | 7 | |
| Goddard Glenn | Senior Vice President, Finance | 0 0% | $32.42 | 0 | 22 | |
| Alenson Carman | Principal Accounting Officer | 0 0% | $32.42 | 0 | 12 |